Pacira Biosciences Grants Molteni Exclusive Rights to Commercialize EXPAREL in EU, UK
MT newswire2026/10/05 12:4108:41 AM EDT, 10/05/2026 (MT Newswires) -- Pacira Biosciences (PCRX) said Monday it has granted Molteni Farmaceutici exclusive rights to distribute and commercialize EXPAREL in the European Union and the United Kingdom. Under the agreement, Pacira will receive an undisclosed upfront payment, a supply price and royalties on future sales of EXPAREL, a local analgesic for postsurgical pain management. Pacira will manufacture the product. Molteni will lead regulatory, market-access and commercialization activities across the licensed territories, Pacira said. The company plans to launch EXPAREL sequentially in Italy, Germany, Austria and Poland, while pursuing approval in Switzerland. The first commercial sale is expected in 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
About 700,000 BTC have flowed out of exchanges in the past year.
Korean retail investors shift to the US in Q3: Sold over 5.5 trillion won of Korean stocks, purchased more than 10 trillion won of US stocks
In the third quarter, Korean retail investors made net purchases of US stocks worth approximately 10.15 trillion won, marking a complete reversal from the previous pattern in the first half of the year, when they made net purchases of nearly 100 trillion won in KOSPI stocks. In September alone, the sell-off amount reached as high as 14.2 trillion won. Analysts attribute this shift to a combination of factors: a sharp decline in KOSPI at high levels, the continued strength of the US stock market driven by AI themes, and the appreciation of the Korean won reducing currency exchange costs.
Crypto prices
More
